An Open Label, Multi-center, Randomized Study to Compare Efficacy and Safety of Daptomycin to Semi-synthetic Penicillins or Vancomycin in the Treatment of Elderly Patients (Aged greater than or equal to 65 Years) With Complicated Skin and Soft Tissue Infections.

Trial Profile

An Open Label, Multi-center, Randomized Study to Compare Efficacy and Safety of Daptomycin to Semi-synthetic Penicillins or Vancomycin in the Treatment of Elderly Patients (Aged greater than or equal to 65 Years) With Complicated Skin and Soft Tissue Infections.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2013

At a glance

  • Drugs Daptomycin (Primary) ; Cloxacillin; Flucloxacillin; Oxacillin; Vancomycin
  • Indications Bacteraemia; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 14 Apr 2012 Additional investigational drug identified as (Flucloxacillin, Oxacillin) as reported by ClinicalTrials.gov.
    • 14 Apr 2012 Actual end date (Mar 2011) added as reported by European Clinical Trials Database record.
    • 14 Apr 2012 Planned number of patients changed from 120 to 146 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top